BiotechTube

Rebif®

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Clinically Isolated Syndrome

Conditions

Clinically Isolated Syndrome

Trial Timeline

Oct 1, 2005 → Nov 1, 2008

NCT ID
NCT00287079

About Rebif®

Rebif® is a phase 3 stage product being developed by Merck for Clinically Isolated Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00287079. Target conditions include Clinically Isolated Syndrome.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT01791244ApprovedCompleted
NCT00287079Phase 3Completed

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85